Pemphigus vulgaris (PV) is a rare, life-threatening and often misdiagnosed autoimmune disease.
Long-term effectiveness and safety of rituximab for the treatment of pemphigus in Chinese population
Data of rituximab (RTX) therapy for pemphigus in Chinese population were scarce; the study aimed to assess the long-term effects and safety of RTX for the treatment of pemphigus in clinical practice.
A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
In this Phase 3, randomized, double-blind, double-dummy, superiority, active-control trial, patients with moderate to severe pemphigus vulgaris were randomized to either rituximab or mycophenolate mofetil for 52 weeks. The primary outcome was the proportion of patients who achieved sustained complete remission for at least four consecutive months. Secondary outcomes included cumulative oral corticosteroids, total number of flares, time to sustained complete remission, time to flare, and change in health-related quality of life. Safety was also assessed.
Symposium, Talk 1: Recent Advances and Current Challenges in PV
Professor Pascal Joly presents rationale for assessing rituximab for the treatment of patients with pemphigus vulgaris (PV). Efficacy and safety from the pivotal Ritux 3 trial are presented, as well as data from a recent cost-benefit analysis of rituximab in PV. Remaining challenges and unanswered questions are also discussed.
Symposium, Talk 2: Tales from the Clinic
Dr. Barbara Horvath presents first-hand experience in how patients with pemphigus vulgaris (PV) are managed at her clinic at the Center for Blistering Diseases in Groningen, Netherlands. Considerations for rituximab treatment are discussed. A case study of a patient with PV who received rituximab is presented.
Symposium, Talk 3: Interactive Patient Case Study Presentation and Discussion
Professor Pascal Joly and Dr. Barbara Horvath present a case study of a patient with pemphigus vulgaris. In their presentation, they engage the audience in different treatment considerations for the patient. The newly revised French recommendations for the management of pemphigus are also discussed.
HCP Interview: Experience on the treatment of PV patients and recent clinical trial data
In this interview, a prominent expert in pemphigus share his experience on the treatment of PV patients and recent clinical trial data.
PV Patient Interview Part 1: From first symptoms to diagnosis
In this patient interview, a patient with pemphigus vulgaris (PV) provides tangible insights on the PV patient journey from first symptoms to diagnosis.
PV Patient Interview Part 2: Burden of disease and treatment
In this patient interview, a patient with pemphigus vulgaris (PV) provide tangible insights on the PV patient burden of disease and treatment.
HCP Interview: Experience on the diagnostic and treatment journey of PV patients
In this interview, a prominent expert in pemphigus share her experience on the diagnostic and treatment journey of her PV patients.